Adverum Biotechnologies to Present at Upcoming Investor Conferences

Tuesday, February 21, 2017 1:31 PM UTC

MENLO PARK, Calif., Feb. 21, 2017 -- Adverum Biotechnologies, Inc. (Nasdaq:ADVM) a gene therapy company committed to discovering and developing novel medicines for patients suffering from diseases with few or burdensome treatment options, announced today that Amber Salzman, Ph.D., president and chief executive officer of Adverum, will present at two upcoming investor conferences:

Cowen and Company 37th Annual Health Care Conference
Date: Monday, March 6, 2017
Time: 2:40pm ET
Location: Boston, MA
29th Annual ROTH Conference
Date: Monday, March 13, 2017
Time: 7:30am PT
Location: Laguna Niguel, CA

The audio portions of the corporate presentations will be accessible live through the investors’ section of the Company’s website at www.adverum.com. A replay will be available for 14 days following the presentations.

About Adverum Biotechnologies, Inc.
Adverum is a gene therapy company committed to discovering and developing novel medicines that can offer life-changing benefits to patients living with rare diseases or diseases of the eye who currently have limited or burdensome treatment options. Adverum has a robust pipeline that includes product candidates to treat wet age-related macular degeneration (wAMD), alpha-1 antitrypsin (A1AT) deficiency, and hereditary angioedema (HAE). Leveraging a next-generation adeno-associated virus (AAV)-based directed evolution platform, the Company generates product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Adverum has collaboration agreements with Regeneron Pharmaceuticals to research, develop, and commercialize gene therapy products for ophthalmic diseases and Editas Medicine to explore the delivery of genome editing medicines for the treatment of inherited retinal diseases. Adverum has clinical development expertise and core capabilities in vector optimization, process development, manufacturing, and assay development. For more information please visit www.adverum.com.

Contact for Adverum: 
Leone Patterson
Chief Financial Officer
Adverum Biotechnologies, Inc.
650-665-7222
[email protected]

Jill Steier
Senior Vice President
The Trout Group LLC
646-378-2946
[email protected]

Editor's Picks

Breathing through your nose when you exercise may make your runs easier

Entrepreneurs are facing a mental health crisis — here's how to help them

Are fish oil supplements as healthy as we think? And is eating fish better?

Will AI kill our creativity? It could – if we don’t start to value and protect the traits that make us human

Does AI have a right to free speech? Only if it supports our right to free thought

How can I lower my cholesterol? Do supplements work? How about psyllium or probiotics?

Why we need to set limits on sperm donation

Aging with a healthy brain: How lifestyle changes could help prevent up to 40% of dementia cases

Seven techniques to avoid weight regain, approved by experts

Adverum Biotechnologies to Present at Upcoming Investor Conferences

Editor's Picks

Welcome to EconoTimes